Free tool
FAERS Monitor: Veklury
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214787 or its brand name (Veklury, Remdesivir). Reports on generic versions are filed under their own applications.
Reports
13,295
Serious
11,170
84% of reports
Hospitalization
4,528
Death reported
3,305
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use2,245
- alanine aminotransferase increased935
- covid-19919
- drug ineffective768
- death762
- bradycardia652
- acute kidney injury630
- aspartate aminotransferase increased629
- respiratory failure552
- covid-19 pneumonia505
- liver function test increased422
- condition aggravated396
- pneumonia334
- drug ineffective for unapproved indication327
- blood creatinine increased323
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 4,479 |
| 2021 | 2,859 |
| 2022 | 2,598 |
| 2023 | 1,647 |
| 2024 | 1,011 |
| 2025 | 536 |
| 2026 | 160 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,040,864 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| covid-19 pneumoniaSignal | 505 | 70.6 | 64.7 | 33,141 |
| liver function test increasedSignal | 422 | 31.7 | 28.8 | 12,282 |
| alanine aminotransferase increasedSignal | 935 | 24.5 | 23.0 | 20,747 |
| bradycardiaSignal | 652 | 19.7 | 18.3 | 11,431 |
| aspartate aminotransferase increasedSignal | 629 | 18.9 | 17.5 | 10,576 |
| respiratory failureSignal | 552 | 12.1 | 11.1 | 5,563 |
| drug ineffective for unapproved indicationSignal | 327 | 9.5 | 8.5 | 2,463 |
| covid-19Signal | 919 | 8.3 | 7.8 | 5,934 |
| blood creatinine increasedSignal | 323 | 7.9 | 7.1 | 1,924 |
| acute kidney injurySignal | 630 | 6.5 | 6.1 | 2,958 |
| off label useSignal | 2,245 | 4.1 | 3.9 | 5,394 |
| condition aggravatedSignal | 396 | 2.1 | 1.9 | 218 |
| pneumonia | 334 | 1.6 | 1.5 | 82 |
| death | 762 | 1.4 | 1.3 | 90 |
| drug ineffective | 768 | 0.9 | 0.9 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.